Background: The aim of this study was to evaluate the treatment reality for outpatients with immune thrombocytopenia (ITP) managed by hematologists in routine care. Patients and Methods: All patients with ITP diagnosed between 06/1995 and 12/2014 in a community-based oncology group practice in Germany were retrospectively analyzed. Results: 422 patients with a median age of 55 years (range 7-91 years) were evaluated. 57% were female and 43% male. Only 198 (47%) patients needed therapy. First-line therapy (n = 198) consisted of steroids in 81%, intravenous immunoglobulins (IVIG) in 12%, and IVIG plus steroids in 6%. Patients received a median of 2 (range 1-10) lines of therapy. The most frequently used treatment modalities were steroids in 93%, IVIG in 55%, splenectomy in 21%, and other immunosuppressive agents (OISA) in 23% of patients. Rituximab and thrombopoietin receptor agonists (TRAs) were used in 10% and 6% only. 9 (2%) patients needed hospitalization due to bleeding complications. 72% of patients achieved a durable remission after their last line of therapy. 1 (0.2%) patient died due to bleeding complications. Conclusion: The treatment modalities most frequently used are steroids, immunoglobulins, splenectomy, and OISA. Rituximab and TRAs are only used infrequently. 72% of ITP patients achieve durable remissions. The rate of hospital admissions due to bleeding complications and the ITP-related mortality are low. The majority of ITP patients can be safely managed by hematologists on an outpatient basis.

Journal Section:
Original Article
Keywords:
Immune thrombocytopenia, ITP, Outpatient management
1.
Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S: Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
[PubMed]
https://doi.org/10.1160/TH07-08-0513
2.
Cines DB, Bussel JB, Liebmann HA, Prak ETL: The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511-6521.
[PubMed]
https://doi.org/10.1182/blood-2009-01-129155
3.
Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ: Immune thrombocytic purpura (ITP) plasma and purified ITP monoclonal antibodies inhibit megakarycytopoiesis in vitro. Blood 2003;102:887-895.
[PubMed]
https://doi.org/10.1182/blood-2002-05-1475
4.
Li X, Zhong H, Bao W, Evangelista J, Haider MA, Bussel J, Yazdanbakhsh K: Defective regulatory B-cell compartment in patients with immune thrombocytopenia. Blood 2012;120:3318-3325.
[PubMed]
https://doi.org/10.1182/blood-2012-05-432575
5.
Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM, Wadenvik H: T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-1124.
[PubMed]
https://doi.org/10.1038/nm921
6.
Frederiksen H, Schmidt K: The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94:909-913.
[PubMed]
7.
Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, Fryzek J, Kaye JA: Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009;145:235-244.
[PubMed]
https://doi.org/10.1111/j.1365-2141.2009.07615.x
8.
UpToDate: Immune thrombocytopenia (ITP) in adults: clinical manifestations and diagnosis. www.uptodate.com/contents/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis?source=machineLearning&search=itp&selectedTitle=1%7E150&sectionRank=1&anchor=H15#H15; accessed July 23, 2015.
9.
Matzdorf A, Eberl W, Giagounidis A, Imbach P, Pabinger I, Wörmann B: Immunthrombozytopenie-Onkopedia-Leitlinien Update: Empfehlungen einer gemeinsamen Arbeitsgruppe der DGHO, ÖGHO, SGH+SSH und GPOH. Oncol Res Treat 2014;37(suppl 2):6-25.
[PubMed]
https://doi.org/10.1159/000356910
10.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA: The American Society of Hematology 2011 evidence-based practice guidelines for immune thrombocytopenia. Blood 2011;117:4190-4207.
[PubMed]
https://doi.org/10.1182/blood-2010-08-302984
11.
Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V.: Niedergelassene Hämatologen und Onkologen in Deutschland. www.bnho.de/startseite.html; accessed June 23, 2015.
12.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines SB, Chong BH, Cooper N, Godeau B, Lechner K, Mazucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood 2009;113:2386-2393.
[PubMed]
https://doi.org/10.1182/blood-2008-07-162503
13.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
[PubMed]
https://doi.org/10.1016/0021-9681(87)90171-8
14.
Rodeghiero F, Ruggeri M: Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. Semin Hematol 2015;52:16-24.
[PubMed]
https://doi.org/10.1053/j.seminhematol.2014.10.006
15.
Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A: Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-2554.
[PubMed]
https://doi.org/10.1182/blood.V97.9.2549
16.
Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR: Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122:966-974.
[PubMed]
https://doi.org/10.1046/j.1365-2141.2003.04547.x
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.